TFO Wealth Partners LLC Has $1.03 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

TFO Wealth Partners LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 58,400.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,170 shares of the biopharmaceutical company’s stock after acquiring an additional 1,168 shares during the period. TFO Wealth Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $1,028,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Eudaimonia Advisors LLC lifted its position in Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after acquiring an additional 11 shares during the last quarter. Drive Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 12 shares during the last quarter. MCF Advisors LLC lifted its position in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the last quarter. LCM Capital Management Inc increased its holdings in shares of Regeneron Pharmaceuticals by 2.5% during the 4th quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock worth $427,000 after purchasing an additional 12 shares during the period. Finally, TrinityPoint Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 12 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $6.67 during trading hours on Wednesday, reaching $966.49. 345,990 shares of the company were exchanged, compared to its average volume of 475,347. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The stock’s fifty day moving average is $945.50 and its two-hundred day moving average is $918.05. The company has a market cap of $106.50 billion, a price-to-earnings ratio of 28.75, a P/E/G ratio of 2.03 and a beta of 0.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Finally, Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $989.36.

Check Out Our Latest Analysis on REGN

Insider Transactions at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael S. Brown sold 1,172 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at $1,347,256.52. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,243 shares of company stock worth $53,955,443. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Read More

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.